28096973|t|A fission yeast cell-based system for multidrug resistant HIV-1 proteases
28096973|a|HIV-1 protease (PR) is an essential enzyme for viral production. Thus, PR inhibitors (PIs) are the most effective class of anti-HIV drugs. However, the main challenge to the successful use of PI drugs in patient treatment is the emergence of multidrug resistant PRs (mdrPRs). This study aimed to develop a fission yeast cell-based system for rapid testing of new PIs that combat mdrPRs. Three mdrPRs were isolated from HIV-infected patients that carried seven (M7PR), ten (M10PR) and eleven (M11PR) PR gene mutations, respectively. They were cloned and expressed in fission yeast under an inducible promoter to allow the measurement of PR -specific proteolysis and drug resistance. The results showed that all three mdrPRs maintained their abilities to proteolyze HIV viral substrates (MA â†“ CA and p6) and to confer drug resistance. Production of these proteins in the fission yeast caused cell growth inhibition, oxidative stress and altered mitochondrial morphologies that led to cell death. Five investigational PIs were used to test the utility of the established yeast system with an FDA - approved PI drug Darunavir (DRV) as control. All six compounds suppressed the wildtype PR (wtPR) and the M7PR -mediated activities. However, none of them were able to suppress the M10PR or the M11PR. The three clinically isolated mdrPRs maintained their viral proteolytic activities and drug resistance in the fission yeast. Furthermore, those viral mdrPR activities were coupled with the induction of growth inhibition and cell death, which could be used to test the PI activities. Indeed, the five investigational PIs and DRV suppressed the wtPR in fission yeast as they did in mammalian cells. Significantly, two of the high level mdrPRs (M10PR and M11PR) were resistant to all of the existing PI drugs including DRV. This observation underscores the importance of continued searching for new PIs against mdrPRs.
28096973	2	15	fission yeast	T004	C0178453
28096973	2	33	fission yeast cell-based system	T062	C1520210
28096973	38	57	multidrug resistant	T032	C0242640
28096973	58	73	HIV-1 proteases	T116,T126	C0917721
28096973	74	88	HIV-1 protease	T116,T126	C0917721
28096973	90	92	PR	T116,T126	C0917721
28096973	110	116	enzyme	T116,T126	C0014442
28096973	121	137	viral production	T043	C0042774
28096973	145	158	PR inhibitors	T121	C0162714
28096973	160	163	PIs	T121	C0162714
28096973	197	211	anti-HIV drugs	T121	C0376565
28096973	266	268	PI	T121	C0162714
28096973	269	274	drugs	T121	C0013227
28096973	278	285	patient	T101	C0030705
28096973	286	295	treatment	T061	C0087111
28096973	316	339	multidrug resistant PRs	T116,T126	C0917721
28096973	341	347	mdrPRs	T116,T126	C0917721
28096973	355	360	study	T062	C2603343
28096973	380	393	fission yeast	T004	C0178453
28096973	380	411	fission yeast cell-based system	T062	C1520210
28096973	422	429	testing	T169	C0039593
28096973	437	440	PIs	T121	C0162714
28096973	453	459	mdrPRs	T116,T126	C0917721
28096973	467	473	mdrPRs	T116,T126	C0917721
28096973	493	505	HIV-infected	T047	C0019693
28096973	506	514	patients	T101	C0030705
28096973	535	539	M7PR	T116,T126	C0917721
28096973	547	552	M10PR	T116,T126	C0917721
28096973	566	571	M11PR	T116,T126	C0917721
28096973	573	575	PR	T116,T126	C0917721
28096973	576	590	gene mutations	T045	C0596611
28096973	616	622	cloned	T059,T063	C0598888
28096973	627	636	expressed	T045	C0017262
28096973	640	653	fission yeast	T004	C0178453
28096973	663	681	inducible promoter	T114,T123	C0086860
28096973	710	712	PR	T116,T126	C0917721
28096973	723	734	proteolysis	T044	C0597304
28096973	739	754	drug resistance	T038	C0013203
28096973	790	796	mdrPRs	T116,T126	C0917721
28096973	827	837	proteolyze	T044	C0597304
28096973	838	841	HIV	T005	C0019682
28096973	842	858	viral substrates	T167	C3891814
28096973	860	862	MA	T116,T123	C0042738
28096973	865	867	CA	T116,T123	C0042738
28096973	872	874	p6	T116,T126	C0917721
28096973	890	905	drug resistance	T038	C0013203
28096973	927	935	proteins	T116,T126	C0917721
28096973	943	956	fission yeast	T004	C0178453
28096973	964	986	cell growth inhibition	T043	C2244509
28096973	988	1004	oxidative stress	T049	C0242606
28096973	1009	1043	altered mitochondrial morphologies	T033	C4014650
28096973	1056	1066	cell death	T043	C0007587
28096973	1073	1088	investigational	T080	C1517586
28096973	1089	1092	PIs	T121	C0162714
28096973	1142	1154	yeast system	T062	C1520210
28096973	1163	1166	FDA	T093	C0041714
28096973	1169	1177	approved	T080	C0205540
28096973	1178	1180	PI	T121	C0162714
28096973	1181	1185	drug	T121	C0013227
28096973	1186	1195	Darunavir	T109,T121	C1435444
28096973	1197	1200	DRV	T109,T121	C1435444
28096973	1205	1212	control	T096	C0009932
28096973	1222	1231	compounds	T121	C0162714
28096973	1232	1242	suppressed	T169	C1260953
28096973	1247	1255	wildtype	T028	C1883559
28096973	1247	1258	wildtype PR	T116,T126	C0917721
28096973	1260	1264	wtPR	T116,T126	C0917721
28096973	1274	1278	M7PR	T116,T126	C0917721
28096973	1289	1299	activities	T052	C0441655
28096973	1336	1344	suppress	T169	C1260953
28096973	1349	1354	M10PR	T116,T126	C0917721
28096973	1362	1367	M11PR	T116,T126	C0917721
28096973	1399	1405	mdrPRs	T116,T126	C0917721
28096973	1423	1428	viral	T005	C0042776
28096973	1429	1451	proteolytic activities	T044	C0597304
28096973	1456	1471	drug resistance	T038	C0013203
28096973	1479	1492	fission yeast	T004	C0178453
28096973	1513	1524	viral mdrPR	T116,T126	C0917721
28096973	1525	1535	activities	T044	C0597304
28096973	1558	1567	induction	T169	C0205263
28096973	1571	1588	growth inhibition	T043	C2244509
28096973	1593	1603	cell death	T043	C0007587
28096973	1637	1639	PI	T121	C0162714
28096973	1640	1650	activities	T052	C0441655
28096973	1669	1684	investigational	T080	C1517586
28096973	1685	1688	PIs	T121	C0162714
28096973	1693	1696	DRV	T109,T121	C1435444
28096973	1697	1707	suppressed	T169	C1260953
28096973	1712	1716	wtPR	T116,T126	C0917721
28096973	1720	1733	fission yeast	T004	C0178453
28096973	1749	1764	mammalian cells	T025	C1512977
28096973	1803	1809	mdrPRs	T116,T126	C0917721
28096973	1811	1816	M10PR	T116,T126	C0917721
28096973	1821	1826	M11PR	T116,T126	C0917721
28096973	1833	1842	resistant	T169	C0332325
28096973	1866	1868	PI	T121	C0162714
28096973	1869	1874	drugs	T121	C0013227
28096973	1885	1888	DRV	T109,T121	C1435444
28096973	1965	1968	PIs	T121	C0162714
28096973	1977	1983	mdrPRs	T116,T126	C0917721